Benzoic acid, 3,4-dimethoxy-, (2E)-2-[(3,4-dimethoxyphenyl)methylene]-1-methylhydrazide manufacturers
- LASSBio-1366
-
- $2500.00
-
2026-05-11
- CAS:1396397-03-7
- Purity:
- Supply Ability: 10g
|
| | Benzoic acid, 3,4-dimethoxy-, (2E)-2-[(3,4-dimethoxyphenyl)methylene]-1-methylhydrazide Basic information |
| | Benzoic acid, 3,4-dimethoxy-, (2E)-2-[(3,4-dimethoxyphenyl)methylene]-1-methylhydrazide Chemical Properties |
| Boiling point | 502.9±60.0 °C(Predicted) | | density | 1.13±0.1 g/cm3(Predicted) | | pka | -0.08±0.70(Predicted) |
| | Benzoic acid, 3,4-dimethoxy-, (2E)-2-[(3,4-dimethoxyphenyl)methylene]-1-methylhydrazide Usage And Synthesis |
| Description | LASSBio-1366 is an adenosine A2a receptor agonist. It acts by attenuating the progression of monocrotaline-induced pulmonary hypertension. | | Uses | PDE4-IN-20 is a selective submicromolar phosphodiesterase-4 (PDE4) inhibitor with anti-TNF-α properties. PDE4-IN-20 exhibits significant biological activity in vitro and in vivo. The mechanism of action of PDE4-IN-20 is supported by molecular modeling studies, which reveal its binding mode with PDE4. PDE4-IN-20 was optimized in further conformational analysis and showed pharmacological characteristics similar to those of known PDE4 inhibitors[1]. | | References | [1] Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors |
| | Benzoic acid, 3,4-dimethoxy-, (2E)-2-[(3,4-dimethoxyphenyl)methylene]-1-methylhydrazide Preparation Products And Raw materials |
|